Gilead 3Q Revenues: $6.5 billion (-13%) 3Q Earnings: $2.7 billion (-18%) YTD Revenues: $20.2 billion (-13%) YTD Earnings: $8.5 billion (-18%) Comments: Antiviral product sales, which include HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.8 billion in the quarter, down 15%.HIV and HBV product sales were $3.6 billion, up 3% primarily due to the continued uptake of our tenofovir alafenamide (TAF) based products, Genvoya, Descovy, and Odefsey. HCV product sales, ...